148 related articles for article (PubMed ID: 32817080)
1. Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy.
Klein S; Quaas A; Noh KW; Cartolano M; Abedpour N; Mauch C; Quantius J; Reinhardt HC; Buettner R; Peifer M; Helbig D
Clin Cancer Res; 2020 Nov; 26(21):5638-5645. PubMed ID: 32817080
[TBL] [Abstract][Full Text] [Related]
2. Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.
Klein S; Mauch C; Wagener-Ryczek S; Schoemmel M; Buettner R; Quaas A; Helbig D
Cancer Immunol Immunother; 2019 Jun; 68(6):973-982. PubMed ID: 30963193
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
[TBL] [Abstract][Full Text] [Related]
4. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract][Full Text] [Related]
5. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Ihle MA; Pütz K; Tantcheva-Poor I; Mauch C; Büttner R; Quaas A
Oncotarget; 2016 Apr; 7(16):21763-74. PubMed ID: 26943575
[TBL] [Abstract][Full Text] [Related]
6. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
8. Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.
Chen SX; Eichenfield DZ; Orme C; Hinds B
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045146
[TBL] [Abstract][Full Text] [Related]
9. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Griewank KG; Schilling B; Murali R; Bielefeld N; Schwamborn M; Sucker A; Zimmer L; Hillen U; Schaller J; Brenn T; Schadendorf D; Mentzel T
Mod Pathol; 2014 Apr; 27(4):502-8. PubMed ID: 24030750
[TBL] [Abstract][Full Text] [Related]
11. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Mauch C; Buettner R; Quaas A
J Cutan Pathol; 2018 Dec; 45(12):880-885. PubMed ID: 30155964
[TBL] [Abstract][Full Text] [Related]
13. Undifferentiated Sarcoma as Intermediate Step in the Progression of Malignant Melanoma to Rhabdomyosarcoma: Histologic, Immunohistochemical, and Molecular Studies of a New Case of Malignant Melanoma With Rhabdomyosarcomatous Differentiation.
Tran TAN; Linos K; de Abreu FB; Carlson JA
Am J Dermatopathol; 2019 Mar; 41(3):221-229. PubMed ID: 30085960
[TBL] [Abstract][Full Text] [Related]
14. TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study.
Zreik RT; Carter JM; Sukov WR; Ahrens WA; Fritchie KJ; Montgomery EA; Weiss SW; Folpe AL
Hum Pathol; 2016 Jul; 53():14-24. PubMed ID: 26980036
[TBL] [Abstract][Full Text] [Related]
15. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
16. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
18. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
19. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
20. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors.
Klein S; Persa OD; Mauch C; Noh KW; Pappesch R; Wagener-Ryczek S; Buettner R; Quaas A; Helbig D
Oncoimmunology; 2019; 8(12):e1665977. PubMed ID: 31741767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
